Meiji And Dong-A Start European Ustekinumab Trial

Dosing Of Phase I Subjects Underway

 
• By Aidan Fry
  
Meiji
Meiji Seika and partner Dong-A have started dosing in a Phase I study for biosimilar ustekinumab • Source: Shutterstock
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Biosimilars

More from Products